GlassScriptPhysician profile
Lance W Hudson
NPI 1760462634
$4,217.67
in general payments reported to CMS, 2019-2025
18 companies · $727 in 2025
The $727 reported for 2025 was more than what 98% of Nurse Anesthetist, Certified Registered providers received nationally (typical 2025 total: $45.72).
See the full distribution for Nurse Anesthetist, Certified Registered
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $533 · 2022: $913 · 2023: $1,267 · 2024: $777 · 2025: $727.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,771.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,771.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,140.80 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $974.76 | 2021-2024 | Xifaxan, Plenvu, Trulance |
| Janssen Biotech, INC. | $433.77 | 2022-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $390.70 | 2021-2025 | Entyvio, Eohilia |
| Qol Medical, LLC | $214.91 | 2021-2024 | Sucraid, Sucraid |
| Merck Sharp & Dohme LLC | $212.38 | 2021-2024 | Dificid, Zinplava |
| Aimmune Therapeutics, INC. | $149.50 | 2024-2025 | Zenpep, Vowst |
| Lilly USA, LLC | $125.90 | 2024-2025 | Omvoh |
| Nestle Healthcare Nutrition INC. | $95.15 | 2023 | |
| Ferring Pharmaceuticals INC. | $83.98 | 2023 | Rebyota, Cimzia |
| Intercept Pharmaceuticals, INC. | $77.86 | 2021-2022 | |
| Ardelyx, INC. | $73.36 | 2024-2025 | Ibsrela |
| Braintree Laboratories, INC. | $73.02 | 2022-2025 | Sutab, Suflave |
| Madrigal Pharmaceuticals | $46.84 | 2024-2025 | Rezdiffra, Resmetirom |
| Redhill Biopharma INC. | $39.65 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $37.81 | 2025 | Dupixent |
| Mirum Pharmaceuticals, INC. | $23.92 | 2025 | Livmarli |
| Azurity Pharmaceuticals, INC. | $23.36 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lance Hudson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.